Source: Annual Congress 2006 - Pulmonary hypertension: thromo-embolic processes
Disease area: Pulmonary vascular diseases

Abstract

Background: Papworth Hospital NHS Trust is the nationally recognised centre in the UK to perform PEA surgery in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). CAMPHOR is a disease specific Health Related Quality of Life (HRQL) measure developed and validated for use in patients with Pulmonary Hypertension. (QoL Research 2006;15(1). We examine the impact of PEA on CAMPHOR three months following surgery. We also compared changes in scores against the Minimal Importance Difference (MID), defined as mean change in score at which patients experience the smallest perceived benefit following treatment.
Method: CAMPHOR symptom, activity and QoL scores obtained 3 months post PEA were compared with paired values obtained immediately prior to PEA in CTEPH subjects. Individual scores were also compared against the MID to assess magnitude of response to surgery in HRQL and QOL.
Results: n=32 (17:15 F:M) Mean age 54 years (21 to 73). There was a statistically significant improvement in CAMPHOR scores in all 3 domains following PEA (p<0.001). Mean change was 9.8 (SEM 1.2) for symptoms, 6.6 (SEM 1.0) for activity and 6.3 (SEM 1.0) for QoL. In addition, the symptom score, activity score and QOL score surpassed the MID in 29/32 (91%), 27/32 (84%) and 25/32 (83%) patients respectively.
Discussion: CTEPH patients experience severely reduced HRQL as a consequence of their disease. PEA surgery improves HRQL in subjects suitable for this therapeutic option. The change following PEA is assessed by most patients as surpassing the minimum level of change in activities, symptoms and QoL required for them to experience an improvement in their well-being.

Rating:

Share or cite this content

Citations should be made in the following way:
N. Doughty, L. Sharples, J. Suntharalingam, D. Jenkins, J. Pepke-Zaba (Cambridge, United Kingdom). Impact of pulmonary endarterectomy (PEA) on quality of life as assessed by CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR). Eur Respir J 2006; 28: Suppl. 50, 2373

Member's Comments

No comment yet.

Related content which might interest you: The responsiveness and validity of the CAMPHOR Utility Index Source: Eur Respir J 2008; 32: 1513-1519 Year: 2008 Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Studying quality of life in PAH: Patient-reported outcome assessment and psychosocial evaluation in a 6 months follow-up Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Correlations between clinical variables and quality of life in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Responsiveness of the EQ-5D to Pulmonary Rehabilitation (PR) Source: International Congress 2018 – Additional latest insights in pulmonary rehabilitation for chronic lung diseases Year: 2018 Impact of riociguat on health-related quality of life (HRQoL) in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Effects of Pulmonary Rehabilitation (PR) on Exercise Capacity (EC) and Quality of Life (QOL) in Indian Patients with Severe COPD Source: International Congress 2017 – Latest insights into pulmonary rehabilitation in COPD Year: 2017 Is pulmonary endarterectomy (PEA) beneficial for the elderly? An analysis of quality of life (QoL) outcomes for older patients Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Prognostic value of outcome variables at follow-up in patients with PAH Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 A retrospective study of depressive illness in patients with pulmonary hypertension (PH) at a specialist centre Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 The German version of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) – Four-stage translation and validation Source: Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models Year: 2012 Reliability and validity of TAPQOL questionnaire for the assessment of global health related quality of life (HRQL) in children with Paediatric Central Airway Obstructive Disease (PCAOD) Source: International Congress 2017 – Paediatric bronchology in clinical practice Year: 2017 Assessing the financial impact of pulmonary hypertension: a survey by the UK Pulmonary Hypertension Association (PHA-UK) Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Physical activity (PA) in pulmonary arterial hypertension (PAH) can be predicted by questionnaire Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Asthma control (AC) and Quality of life (QoL) one year after Pulmonary Rehabilitation (PR) Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Evaluation of health related quality of life in patients under LTOT with the Severe Respiratory Insufficiency questionnaire (SRI) Source: Annual Congress 2010 - Palliative care, oxygen and community care for chronic lung disease Year: 2010 Evaluation of a novel clinic for management of Chronic Thromboembolic Pulmonary Disease (CTED) and associated Pulmonary Hypertension (CTEPH). Source: International Congress 2017 – PAH and CTEPH Year: 2017 Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013